Adult urologySafety assessment of terazosin in thetreatment of patients with symptomatic benign prostatic hyperplasia: A combined analysis*
References (23)
- et al.
Effects of prazosin in patients with benign prostatic obstruction
J Urol
(1983) - et al.
The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain
J Urol
(1988) - et al.
A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia
J Urol
(1992) - et al.
The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia
J Urol
(1992) - et al.
Post-prostatectomy impotence
J Urol
(1976) - et al.
The use of alpha-blockers in the a ngement of benign prostatic hyperplasia
NY State J Med
(1993) - et al.
Alpha-blockade in the management of benign prostatic hyperplasia
- et al.
Alpha-adrenergic blockers in prostatism
Br J Surg
(1977) - et al.
The use of alphadrenergic blockers in benign prostatic obstruction
Br J Urol
(1976) - et al.
A placebo-controlled double-blind study of the effect of phenoxybenzami in benign prostatic obstruction
Br J Urol
(1978)
Bladder outflow obstruction treated with phenoxybenzamine
Br J
Cited by (65)
Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial
2016, Journal of UrologyCitation Excerpt :Previous studies have shown variable incidences of sexual AEs with α-blocker BPH medical therapies. An assessment of safety data from 6 BPH studies ranging in duration from 2 to 6 months indicated that the incidence of erectile dysfunction was 2% for terazosin compared to 1% for placebo.12 In another pooled analysis of adverse event reports from 7 double-blind, placebo controlled terazosin clinical trials 2 months to 1 year in duration abnormal ejaculation was reported in 1% of men treated with terazosin compared with 0.3% treated with placebo (p <0.01).13
Pharmacologic complications
2009, Complications of Urologic Surgery: Expert ConsultCombined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line
2009, Cancer LettersCitation Excerpt :But the reported IC50 of terazosin on prostate cancer cells is higher than 100 μM (about 46 μg/ml) [12,13,19]. We used lower and nontoxic dosage of terazosin (1 μg/ml) to decrease adverse effects [41–43], and in combination with 5 μg/ml of genistein to produce more effective anticancer results suggesting that this combination strategy would be an attractive clinical option. Many anticancer agents and DNA-damaging agents arrest the cell cycle at G1, S, or G2/M phase and induce apoptotic cell death [44–49].
A review of combination therapy in patients with benign prostatic hyperplasia
2007, Clinical TherapeuticsHepatotoxicity induced by terazosin [3]
2003, Medicina Clinica
- *
This research was supported by a grant from Abbott Laboratories, Abbott Park, Illinois.